Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify patients with persisting tumor cells after standard
epirubicin-containing treatment to test a non-cross resistant chemotherapy regimen
(docetaxel) for these patients, and to explore the analysis of disseminated tumor cells in
bone marrow as a surrogate marker for clinical outcome.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Alesund Hospital Helse Stavanger HF Sorlandet Hospital HF Sykehuset i Vestfold HF Sykehuset Innlandet HF Sykehuset Ostfold Ullevaal University Hospital University of Tromso